Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma.

Trial Profile

Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Cisplatin
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 22 Mar 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 18 Jun 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top